CannaCiencia promotes Medicinal Cannabis in the medical, scientific and business agenda of the country.

CannaCiencia promotes Medicinal Cannabis in the medical, scientific and business agenda of the country.

With close to 350 attendees, 24 presentations by experts in medicinal cannabis and a commercial space that gathered brands and enterprises at national and international level, Cannaciencia, the first Cannabis Science Symposium of the Americas is consolidated as the platform to educate, visualize advances scientists, academics, doctors, pharmacists and technologists in this field, and the challenges and opportunities for the development of the cannabis industry in Colombia.

 

The first edition of CannaCiencia leaves a good balance. The participation of world authorities such as Dr. Uma Dhanabalam, expert, activist, defender and educator of the therapeutic use of medicinal cannabis; and Dr. Sue Sisley, who has been working on the investigation of the use of cannabis in the treatment of post-traumatic stress in veterans of war in the United States, had a great reception as a reference of the advances and barriers that currently face in their exercise professional, and education as the first path to destigmatization both in the medical community and in the general imagination.

 

In this context, the educational impact is highlighted as one of the main achievements of the event, especially with the topics related to the analytical laboratory and quality control, where there was a great lack of knowledge in the country. The outstanding participation of Scott Kuzdzal, an expert in toxicology and therapeutic drug monitoring, emphasized the responsibility of the industry in the implementation of effective processes to guarantee the correct labeling and the production of safe and contaminant-free medicinal cannabis.

 

For his part, Joshua Crossney, Founder of jCanna and the Cannabis Science Conference in the USA, presented the advances in academic research, in its commitment to close the gap between analytical sciences and the medical industry of cannabis to help improve quality of the products that patients use.

 

CannaCiencia also made visible the Colombian scientists and the research they are currently carrying out, offering them a platform for discussion, interconnection and search for funding, at a point where it is crucial to promote research for medical, clinical and pharmaceutical development.

 

The context of legalization and regulation of Medicinal Cannabis in Colombia also opened a door for industry experts and investors from countries where the business is already on a journey, which focus on the opportunities and potential of the nascent local industry. The presence of important investors in Cannaciencia such as Tuatara Capital of New York, support the importance of this scenario.

 

In the same way, a new and growing generation of entrepreneurs was identified around the medicinal cannabis industry, eager for ideas, information and alternatives to access capital.

 

“We are facing the challenges of an industry that is at the starting point. The economic impact of the emerging industry worldwide is historic, with compound annual growth rates of up to 34% (CAGR). It requires a huge venture capital education (risk capital) component, clear regulation by the competent financial authorities and inclusion for the Latino community in the emerging industry worldwide, “says Carol Ortega Algarra, CEO of Muisca Capital Group, the first Latin investment management firm, Founder of CannaCiencia and the Network of Cannabis Entrepreneurs of Colombia ”

 

For his part, Ricardo Martinez Executive Director of CannaCiencia and the Network of Cannabis Entrepreneurs of Colombia, says that the 3 most outstanding results of the symposium were: advanced scientific education given to attendees, visualization of Latin American scientists and their findings , derived from research projects, and the visit of multiple investment firms and family offices in North America, Europe and Asia. CannaCiencia is positioned as an international benchmark in science related to Medicinal Cannabis.

 

As a result, in August, the first cycle of training for entrepreneurs linked to the Network of Cannabis Entrepreneurs of Colombia and individuals interested in training will begin, with the first CannaCiencia Workshop, which will include the participation of specialists in cultivation, production, transformation and economic science of medicinal cannabis.

Post-traumatic Stress in the armed forces

Post-traumatic Stress in the armed forces

Anyone, regardless of their age or circumstance, who has experienced a traumatic event may be susceptible to PTSD (Post Traumatic Stress Disorder – the inability of some people to extinguish traumatic memories).

 

After a traumatic event, patients with PTSD are likely to feel feelings and thoughts related to the trauma, experience nightmares, memories, emotional distress, and hypervigilance among a host of other symptoms.

 

Post-traumatic stress is mainly due to fear learned. When you have more fear learned, that will induce a state of hypervigilance and that can also cause nightmares and terrors at night. This learned fear makes it difficult to modulate feelings and reactions, especially with respect to situations that trigger memory or trauma experience.

 

The extinction of memory occurs naturally, organically in the average population. However, some people who have experienced a trauma or traumatic event have an impairment to their natural capacity for memory extinction.

 

According to the US National Center for PTSD UU., More than 8% of the US population. UU suffers from post-traumatic stress disorder, 26% of which are men and women of military service. In Israel, approximately 9% of citizens have been diagnosed with post-traumatic stress disorder, a country where military service and reserve duty is mandatory, and who have generally lived in permanent war, post-traumatic stress disorder It is frequent. Canada has some of the highest rates of PTSD, with an estimated 9.4 percent of the population experiencing some form of the disease

 

Conventional treatments against PTSD include powerful sedatives, antidepressants, anti-anxiety drugs and, in extreme cases, antipsychotics. Most of these medications are based on opioids, which can cause a variety of devastating side effects (restlessness, anxiety) and long-term problems (tachycardia, addiction, and suicidal tendencies). This has led to an epidemic of opioids, which has led to a considerable increase in deaths.

 

This has become in these countries a problem that has demanded attention and answers aimed at solving it in a different way.

 

Medical cannabis has been shown to support the extinction capabilities of the body’s endogenous memory, reducing the ability of traumatic memories to trigger the symptoms of PTSD.

 

Cannabis is a much better and safer and more effective alternative. Because of its antisuppressive, anti-stress and anti-depressant properties, it also allows reducing the deficiency of Anandamide, common in patients with PTSD.

 

The most advanced countries in the application of medical cannabis in PTSD are: United States, where the Dr. Sue Sisley is internationally recognized expert, in Canada is Dr. Mike Hart who along with movements such as Marijuana for Trauma (https://mftgroup.ca/) have become standard bearers of the TEP, in Israel are Dr. Irit Akirav of the University of Haifa, and Dr. Yasmin Hurd, and movements such as: Lochamim Lchaim – Fighting for Life (http://lohamim.org.il/).

 

Dr. Sue Sisley is the Principal Investigator of the only FDA-approved randomized controlled trial in the world that examines the safety and efficacy of medical cannabis in combat veterans with treatment-resistant post-traumatic stress disorder. The study is the largest awarded by the Department of Public Health and Environment CDPHE Colorado (US $ 2.1M)

 

Veterans represent 20% of national suicide rate, this translates into 22 veterans who commit suicide every day, in three years the number of veterans who have committed suicide totals 24,000. These veterans correspond to those resistant to the treatment of PTSD.

 

Patients with PTSD suffer a comorbidity rate, which means that they experience more than one condition at a time. 79% of women and 88% of men diagnosed with PTSD also suffer from depression, substance abuse and anxiety disorders. Given the growing evidence that cannabis is a treatment for depression, anxiety and substance abuse, the potential benefit of cannabis treatment for comorbidity is very promising. This, combined with a growing body of evidence that the endocannabinoid system has a role in reducing fear and anxiety, suggests that cannabinoids can also have positive effects in reducing suicidal thoughts and behaviors.

 

There is great potential for medical cannabis to become a multi-therapy, rather than having to take as many different medications for all the symptoms and parallel conditions as monotherapy.